News & Updates

Polaprezinc plus PPI noninferior to rebamipide plus PPI in ESD-induced ulcers

01 Mar 2021 by

Treatment with polaprezinc plus proton pump inhibitor (PPI) is noninferior to rebamipide plus PPI in terms of ulcer healing rate at 4 weeks after endoscopic submucosal dissection (ESD), a Korea study has shown.

Polaprezinc plus PPI noninferior to rebamipide plus PPI in ESD-induced ulcers

01 Mar 2021

Pancreatic enzymes supplementation leads to symptomatic recovery in sorafenib-treated HCC

27 Feb 2021

Supplementation with pancreatic enzymes results in symptomatic recovery in hepatocellular carcinoma (HCC), as shown in a study that validated the association between malabsorption (MA) and pancreatic insufficiency (PI) in 10 percent of sorafenib-treated patients.

Pancreatic enzymes supplementation leads to symptomatic recovery in sorafenib-treated HCC

27 Feb 2021

Adjuvant S-1 + docetaxel yields survival benefit for stage III gastric cancer patients following resection

26 Feb 2021 by

A combination therapy of S-1 plus docetaxel in the adjuvant setting is not only superior to S-1 alone for recurrence-free survival (RFS) following D2 gastrectomy for stage III gastric cancer, it also confers overall survival (OS) benefit, according to the updated analysis of the JACCRO GC-07 trial presented at ASCO GICS 2021.

Adjuvant S-1 + docetaxel yields survival benefit for stage III gastric cancer patients following resection

26 Feb 2021

Drug eluting vs covered metal stents: which is more beneficial in malignant biliary strictures?

26 Feb 2021

Drug-eluting (DES) and self-expanding metal stents (SEMS) show similar clinical outcomes, as well as reported adverse events and complications, in patients with malignant biliary strictures, reveals a recent meta-analysis.

Drug eluting vs covered metal stents: which is more beneficial in malignant biliary strictures?

26 Feb 2021

Modified Mediterranean diet halves NAFLD risk

26 Feb 2021 by

A modification of the Mediterranean diet (MED), otherwise called green-MED, may reduce the risk of developing NALFD*, the DIRECT PLUS** trial suggests.

Modified Mediterranean diet halves NAFLD risk

26 Feb 2021

Unrestricted DAA use could reduce HCV incidence in HIV

25 Feb 2021 by

Unrestricted access to direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection in individuals with HIV led to a substantial reduction in HCV incidence, particularly in the key subgroup of men who have sex with men (MSM), according to a retrospective Dutch study.

Unrestricted DAA use could reduce HCV incidence in HIV

25 Feb 2021

Switching from TDF to TAF in chronic HBV does not worsen renal function, BMD

24 Feb 2021 by

Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) did not result in worsening renal function or bone mineral density (BMD) in Asian patients with chronic hepatitis B virus (HBV) infection, according to a small real-world prospective study.

Switching from TDF to TAF in chronic HBV does not worsen renal function, BMD

24 Feb 2021

Following healthy diet, lifestyle factors can help prevent GERD

20 Feb 2021 by

Following five diet and lifestyle factors can help prevent symptoms related to gastroesophageal reflux (GERD), according to the long-running Nurses’ Health Study.

Following healthy diet, lifestyle factors can help prevent GERD

20 Feb 2021

Proteus mirabilis a key bacterium associated with Crohn’s disease

18 Feb 2021 by

Proteus mirabilis is significantly more prevalent in the faeces and gut mucosa of patients with Crohn’s disease (CD) than in healthy individuals and plays a crucial role in CD pathogenesis, researchers from the Chinese University of Hong Kong (CUHK) have shown.

Proteus mirabilis a key bacterium associated with Crohn’s disease

18 Feb 2021

Infigratinib emerges as potential treatment for advanced cholangiocarcinoma

16 Feb 2021 by

Infigratinib may be a suitable second- or later-line treatment option for patients with advanced or metastatic cholangiocarcinoma (CCA) with FGFR2* fusions or rearrangements, according to interim results of a phase II, open-label, single-arm study presented at ASCO GI 2021.

Infigratinib emerges as potential treatment for advanced cholangiocarcinoma

16 Feb 2021

News & Updates

Filter by Specialty:

Specialty:

Polaprezinc plus PPI noninferior to rebamipide plus PPI in ESD-induced ulcers

Polaprezinc plus PPI noninferior to rebamipide plus PPI in ESD-induced ulcers

Pancreatic enzymes supplementation leads to symptomatic recovery in sorafenib-treated HCC

Pancreatic enzymes supplementation leads to symptomatic recovery in sorafenib-treated HCC

Adjuvant S-1 + docetaxel yields survival benefit for stage III gastric cancer patients following resection

Adjuvant S-1 + docetaxel yields survival benefit for stage III gastric cancer patients following resection

Drug eluting vs covered metal stents: which is more beneficial in malignant biliary strictures?

Drug eluting vs covered metal stents: which is more beneficial in malignant biliary strictures?

Modified Mediterranean diet halves NAFLD risk

Modified Mediterranean diet halves NAFLD risk

Unrestricted DAA use could reduce HCV incidence in HIV

Unrestricted DAA use could reduce HCV incidence in HIV

Switching from TDF to TAF in chronic HBV does not worsen renal function, BMD

Switching from TDF to TAF in chronic HBV does not worsen renal function, BMD

Following healthy diet, lifestyle factors can help prevent GERD

Following healthy diet, lifestyle factors can help prevent GERD

Proteus mirabilis a key bacterium associated with Crohn’s disease

Proteus mirabilis a key bacterium associated with Crohn’s disease

Infigratinib emerges as potential treatment for advanced cholangiocarcinoma

Infigratinib emerges as potential treatment for advanced cholangiocarcinoma